非典型腺瘤性增生
腺癌
病理
肺癌
癌变
肺
生物
血管生成
医学
非典型增生
癌症
癌症研究
增生
内科学
作者
Yun-Ching Chen,Chia‐Lang Hsu,Huimin Wang,Shang‐Gin Wu,Yih‐Leong Chang,Jin‐Shing Chen,Yu‐Ching Wu,Yen‐Ting Lin,Ching‐Yao Yang,Mong‐Wei Lin,Jang‐Ming Lee,Shuenn‐Wen Kuo,Ke-Cheng Chen,Hsao‐Hsun Hsu,Pei‐Ming Huang,Yen-Lin Huang,C C Yu,Mehdi Pirooznia,B. Emma Huang,R. Yang,Jin‐Yuan Shih,Pan‐Chyr Yang
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2024-11-21
标识
DOI:10.1158/0008-5472.can-24-0821
摘要
Abstract Lung cancer is the most common cause of cancer mortality globally, and the prevalence of lung adenocarcinoma (LUAD), the most common lung cancer subtype, has increased sharply in East Asia. Early diagnosis leads to better survival rates, but this requires an improved understanding of the molecular changes during early tumorigenesis, particularly in non-smokers. Here, we performed whole exome-sequencing and RNA-sequencing of samples from 94 East Asian patients with precancerous lesions (25 with atypical adenomatous hyperplasia [AAH]; 69 with adenocarcinoma in situ [AIS]) and 73 patients with early invasive lesions (minimally invasive adenocarcinoma [MIA]). Cellular analysis revealed that the activities of endothelial and stromal cells could be used to categorize tumors into molecular subtypes within pathologically defined types of lesions. The subtypes were linked with the radiologically defined type of lesions and corresponded to immune cell infiltration throughout the early progression of LUAD. Spatial transcriptomic analysis revealed the distribution of epithelial cells, endothelial cells, fibroblasts, and plasma cells within MIA samples. Characterization of the molecular lesion subtypes identified positively selected mutational patterns and suggested that angiogenesis in the late-stage AIS type potentially contributes to tissue invasion of the MIA type. This study offers a resource that may help to improve early diagnosis and patient prognosis, and the findings suggest possible approaches for early disease interception.
科研通智能强力驱动
Strongly Powered by AbleSci AI